SCHEMBL352333

SCHEMBL352333

COC1(OC)C(NC(=O)c2cc3ccccc3nc2O)=CC(=O)C2OC21

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPC1 O15118 8/20 0.35
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
POLB P06746 2/20 0.35
PARK7 Q99497 1/20 0.35
CASP3 P42574 2/20 0.34
SENP7 Q9BQF6 2/20 0.34
SENP6 Q9GZR1 2/20 0.34
ATM Q13315 1/20 0.34
SENP8 Q96LD8 1/20 0.34
MAOB P27338 3/20 0.34
RXFP1 Q9HBX9 2/20 0.34
MAOA P21397 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPK1 P28482 1/20 0.34
NOD2 Q9HC29 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5706486 0.81 MEN1 (0.44) RAB9AMAPTSMN1; SMN2NPC1KMT2A
SCHEMBL353750 0.79 KMT2A (0.36) RAB9AMAPTSMN1; SMN2NPC1KMT2A
SCHEMBL352275 0.73 SMN1; SMN2 (0.37) RAB9AMAPTSMN1; SMN2NPC1PARK7
SCHEMBL351631 0.72 PARK7 (0.57) RAB9AMAPTSMN1; SMN2NPC1PARK7
SCHEMBL16234345 0.67 KDM4E (0.51) RAB9AMAPTSMN1; SMN2KMT2AMEN1
SCHEMBL352240 0.66 MAPT (0.43) RAB9AMAPTSMN1; SMN2NPC1POLB
SCHEMBL352431 0.65 PARK7 (0.56) RAB9AMAPTSMN1; SMN2PARK7MAOB
SCHEMBL16650067 0.63 PARK7 (0.54) RAB9AMAPTSMN1; SMN2NPC1KMT2A
SCHEMBL352221 0.61 IKBKB (0.51) RAB9AMAPTSMN1; SMN2NPC1KMT2A
SCHEMBL31133499 0.61 IKBKB (0.51) RAB9AMAPTSMN1; SMN2NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
EP-2411376-A1 INHIBITORS OF NF-KB Profectus Biosciences, Inc. (US) 2012-02-01 EP disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed
WO-2010111460-A1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG RAB9A 2089/4885MAPT 2761/4885SMN1; SMN2 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.